A Study of GC101 TIL in Advanced Melanoma
A phase 2 trial of GC101 TIL, Dacarbazine, Temozolomide in melanoma, run by Shanghai Juncell Therapeutics, now recruiting.
Overview
A Study of GC101 TIL in Advanced Melanoma is a phase 2 interventional study registered as NCT06703398 by Shanghai Juncell Therapeutics, with 98 participants planned, started 2024-12-20 and due to reach its primary completion in 2026-05-12. Interventions recorded: GC101 TIL, dacarbazine, temozolomide, paclitaxel ,platinum or cisplatin. Conditions listed: Melanoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Phase II Study of GC101 in NSCLC
Shares Shanghai Juncell Therapeutics, GC101 TIL.
- TrialA Phase II Trial of LM103 in Advanced Melanoma
Shares Dacarbazine, Temozolomide, Paclitaxel / nab-paclitaxel, Melanoma.
- TrialA Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
Shares Temozolomide, Melanoma.
- TrialIDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
Shares Dacarbazine, Melanoma.
- IdeaA skull ultrasound implant that opens the barrier at every cycle
Shares Temozolomide, Paclitaxel / nab-paclitaxel.
- TrialA Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors
Shares Paclitaxel / nab-paclitaxel, Melanoma.
- TrialA Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizu
Shares Paclitaxel / nab-paclitaxel, Melanoma.
- TrialGEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
Shares Paclitaxel / nab-paclitaxel, Melanoma.